Showing results (81-90 of 137) with videos related to
Sort By:
Pageof 14
Neurology(R) Neuroimmunology & Neuroinflammation|February 12, 2024
Impact of Immune Checkpoint Inhibitors on the Course of Multiple SclerosisGéraldine Androdias, Louise Noroy, Dimitri Psimaras, et al.BMC Medical Research Methodology|May 2, 2021
Intra-database validation of case-identifying algorithms using reconstituted electronic health records from healthcare claims dataNicolas H Thurin, Pauline Bosco-Levy, Patrick Blin, et al.Annals of Clinical and Translational Neurology|September 10, 2021
A meta-analysis comparing first-line immunosuppressants in neuromyelitis opticaJonathan Giovannelli, Jonathan Ciron, Mikael Cohen, et al.Journal of Neuroinflammation|April 25, 2020
Outcome and risk of recurrence in a large cohort of idiopathic longitudinally extensive transverse myelitis without AQP4/MOG antibodiesElisabeth Maillart, Françoise Durand-Dubief, Céline Louapre, et al.Journal of Neurology|February 14, 2019
Correction to: Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adultsAlvaro Cobo-Calvo, María Sepúlveda, Hyacintha d'Indy, et al.Neurology|May 22, 2026
French NOMADMUS Cohort Overview: Landscape Evolution of AQP4+NMOSD and MOGAD From 2010 to 2024Thomas Roux, François-Xavier Lejeune, Romain Casey, et al.Journal of Neurology|January 5, 2019
Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adultsAlvaro Cobo-Calvo, María Sepúlveda, Hyacintha d'Indy, et al.Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|September 23, 2020
Relapses in Patients Treated with High-Dose Biotin for Progressive Multiple SclerosisSophie Mathais, Xavier Moisset, Bruno Pereira, et al.Journal of Neuroinflammation|July 4, 2019
Evaluation of treatment response in adults with relapsing MOG-Ab-associated diseaseAlvaro Cobo-Calvo, María Sepúlveda, Fabien Rollot, et al.JAMA Network Open|June 23, 2023
Association Between Anti-CD20 Therapies and COVID-19 Severity Among Patients With Relapsing-Remitting and Progressive Multiple SclerosisEdouard Januel, David Hajage, Pierre Labauge, et al.Pageof 14